Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Ligand-Induced Changes in Surface μ-Opioid Receptor Number: Relationship to G Protein Activation?

Paulette A. Zaki, Duane E. Keith Jr., George A. Brine, F. Ivy Carroll and Christopher J. Evans
Journal of Pharmacology and Experimental Therapeutics March 2000, 292 (3) 1127-1134;
Paulette A. Zaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duane E. Keith Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George A. Brine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Ivy Carroll
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Evans
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In this study, we explored the relationship between regulation of surface μ-opioid receptor number, ligand-induced G protein activation {measured by [35S]guanosine-5′-O-(3-thio)triphosphate (GTPγS) binding} and second messenger signaling (measured by the inhibition of cAMP accumulation). Etorphine and two isomers ofcis-β-hydroxy-3-methylfentanyl (RTI-1a and RTI-1b), which were full agonists for G protein activation and signaling, caused approximately a 50% loss of surface receptors after 1 h of treatment. Fentanyl and morphine were full agonists for inhibiting cAMP accumulation and partial agonists for stimulating [35S]GTPγS binding and internalization. Although both agonists were ∼80% as efficacious as etorphine in stimulating [35S]GTPγS binding, fentanyl induced a 35% loss of surface receptors, whereas morphine only caused a 10% loss. Additionally, both long- and short-term treatment with the opioid antagonist naloxone caused increases in surface receptors. Unexpectedly, the weak partial agonists buprenorphine and one isomer ofcis-β-hydroxy-3-methylfentanyl (RTI-1d) also were found to cause an increase in surface receptors. Treatment with pertussis toxin (PTX) diminished agonist-induced loss of surface receptors. Furthermore, the abilities of morphine and fentanyl to cause internalization were more impaired after PTX treatment than that of etorphine. PTX treatment also significantly enhanced the increase in surface receptor number caused by 18-h treatment with naloxone and buprenorphine. The results of this study suggest that disruption of G protein coupling by PTX treatment affects ligand-regulated μ-receptor trafficking and that partial agonists for signaling can vary greatly in the ability to regulate the number of surface μ-opioid receptors.

Footnotes

  • Send reprint requests to: Chris Evans, Department of Psychiatry and Biobehavioral Sciences, UCLA-Neuropsychiatry Institute, 760 Westwood Plaza, Los Angeles, CA 90024-1759. E-mail:cevans{at}ucla.edu

  • ↵1 This work was supported by National Institute on Drug Abuse Grant DA-05010. P.A.Z. is a Hatos scholar and recipient of a predoctoral fellowship from the Howard Hughes Medical Institute.

  • Abbreviations:
    GPCR
    G protein-coupled receptor
    HEK
    human embryonic kidney
    GTPγS
    guanosine-5′-O-(3-thio)triphosphate
    PTX
    pertussis toxin
    MOR
    murine μ-opioid receptor
    FITC
    fluorescein isothiocyanate
    RAVE
    relative activity versus endocytosis
    DAMGO
    [d-Ala2,N-(MePhe4,Gly-ol5]-enkephalin, FBS, fetal bovine serum
    • Received August 25, 1999.
    • Accepted August 25, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 292 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 292, Issue 3
1 Mar 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ligand-Induced Changes in Surface μ-Opioid Receptor Number: Relationship to G Protein Activation?
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Ligand-Induced Changes in Surface μ-Opioid Receptor Number: Relationship to G Protein Activation?

Paulette A. Zaki, Duane E. Keith, George A. Brine, F. Ivy Carroll and Christopher J. Evans
Journal of Pharmacology and Experimental Therapeutics March 1, 2000, 292 (3) 1127-1134;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleNEUROPHARMACOLOGY

Ligand-Induced Changes in Surface μ-Opioid Receptor Number: Relationship to G Protein Activation?

Paulette A. Zaki, Duane E. Keith, George A. Brine, F. Ivy Carroll and Christopher J. Evans
Journal of Pharmacology and Experimental Therapeutics March 1, 2000, 292 (3) 1127-1134;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CVN424, a novel GPR6 inverse agonist for Parkinson's disease
  • Methylone Brain Concentrations and Pharmacodynamic Effects
  • Oxysterols and Ethanol
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics